Literature DB >> 22473168

Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer.

Martin J Edelman, Lydia Hodgson, Xiaofei Wang, Robert A Kratzke, Everett E Vokes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22473168      PMCID： PMC3383177          DOI： 10.1200/JCO.2011.41.4581

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.

Authors:  Brian I Rini; Vivian Weinberg; Sarah Dunlap; Alexandra Elchinoff; Nancy Yu; Robert Bok; Jeffery Simko; Eric J Small
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

2.  Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways.

Authors:  K Subbaramaiah; J C Hart; L Norton; A J Dannenberg
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

3.  Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.

Authors:  Nasser K Altorki; Jeffrey L Port; Fan Zhang; Dragan Golijanin; Howard T Thaler; Anna J Duffield-Lillico; Kotha Subbaramaiah; Andrew J Dannenberg
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

4.  A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.

Authors:  Karen L Reckamp; Kostyantyn Krysan; Jason D Morrow; Ginger L Milne; Robert A Newman; Christopher Tucker; Robert M Elashoff; Steven M Dubinett; Robert A Figlin
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

5.  Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

Authors:  Harry J M Groen; Hannie Sietsma; Andrew Vincent; Monique M H Hochstenbag; John W G van Putten; Anke van den Berg; Otilia Dalesio; Bonne Biesma; Hans J M Smit; Ariën Termeer; T Jeroen N Hiltermann; Ben E E M van den Borne; Franz M N H Schramel
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

6.  The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.

Authors:  Mary J Fidler; Athanassios Argiris; Jyoti D Patel; David H Johnson; Alan Sandler; Victoria M Villaflor; John Coon; Lela Buckingham; Kelly Kaiser; Sanjib Basu; Philip Bonomi
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

7.  Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Authors:  Martin J Edelman; Dee Watson; Xiaofei Wang; Carl Morrison; Robert A Kratzke; Scott Jewell; Lydia Hodgson; Ann M Mauer; Ajeet Gajra; Gregory A Masters; Michelle Bedor; Everett E Vokes; Mark J Green
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

8.  Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.

Authors:  Alessandra Fabi; Giulio Metro; Paola Papaldo; Marcella Mottolese; Elisa Melucci; Paolo Carlini; Isabella Sperduti; Michelangelo Russillo; Alain Gelibter; Gianluigi Ferretti; Silverio Tomao; Michele Milella; Francesco Cognetti
Journal:  Cancer Chemother Pharmacol       Date:  2007-12-06       Impact factor: 3.333
  8 in total
  5 in total

1.  COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer.

Authors:  Imtiyaz A Bhat; Roohi Rasool; Iqbal Qasim; Khalid Z Masoodi; Shabeer A Paul; Bashir A Bhat; Farooq A Ganaie; Sheikh A Aziz; Zafar A Shah
Journal:  Tumour Biol       Date:  2014-08-12

2.  Pectin-encrusted gold nanocomposites containing phytic acid and jacalin: 1,2-dimethylhydrazine-induced colon carcinogenesis in Wistar rats, PI3K/Akt, COX-2, and serum metabolomics as potential targets.

Authors:  Malti Arya; Pooja Singh; Chandra B Tripathi; Poonam Parashar; Mahendra Singh; Jovita Kanoujia; Anupam Guleria; Gaurav Kaithwas; Krishna P Gupta; Shubhini A Saraf
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

3.  The Role of Prostaglandin-Endoperoxide Synthase-2 in Chemoresistance of Non-Small Cell Lung Cancer.

Authors:  Xiao-Mian Lin; Wu Luo; Heng Wang; Rong-Zhen Li; Yi-Shan Huang; Lian-Kuai Chen; Xiao-Ping Wu
Journal:  Front Pharmacol       Date:  2019-08-08       Impact factor: 5.810

4.  Aza-BODIPY probe for selective visualization of cyclooxygenase-2 in cancer cells.

Authors:  Thitima Pewklang; Kantapat Chansaenpak; Rung-Yi Lai; Parinya Noisa; Anyanee Kamkaew
Journal:  RSC Adv       Date:  2019-04-30       Impact factor: 4.036

5.  Cyclooxygenase-2 induced β1-integrin expression in NSCLC and promoted cell invasion via the EP1/MAPK/E2F-1/FoxC2 signal pathway.

Authors:  Jinshun Pan; Qinyi Yang; Jiaofang Shao; Li Zhang; Juan Ma; Yipin Wang; Bing-Hua Jiang; Jing Leng; Xiaoming Bai
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.